Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation(TMS) on Brain Derived Neurotrophic Factor (BDNF) in Depressed Patients.
Completed
- Conditions
- Depression
- Registration Number
- NCT00630123
- Lead Sponsor
- Queen's University
- Brief Summary
To investigate the change in brain derived neurotrophic factor (BDNF) between pre and post treatment for patients with depression with either ECT or TMS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
- MDD or bipolar disorder;
- current depressive episode, ham-d17>17 and ymrs<8;
- recommended to receive ECT or TMS as part of clinical care;
- male/female;
- age 18-65;
- inpatient or outpatient;
- comorbid dysthymic disorder, gad, or social anxiety will be included;
- able to give written consent and agree.
Exclusion Criteria
- current manic, hypomanic, or mixed episode, ymrs>7;
- current schizophrenia, anorexia, bulimia, substance dependence (current within past 6 months excluding caffeine and nicotine);
- TMS or ECT in the last 3 months;
- any other primary diagnosis;
- uncontrolled medical illness;
- epilepsy or severe personality disorder at the discretion of the investigators;
- 3 weeks prior to first blood test, antidepressants, mood stabilizers, antipsychotics can not be added or increased;
- pregnant women or women of childbearing potential not willing to use appropriate contraception, nursing women;
- known intolerance or lack of response to treatment receiving as judged by the investigator;
- medical conditions that would affect serum levels of BDNF;
- involvement in planning and conduct of the study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum levels of BDNF. pre and post treatment
- Secondary Outcome Measures
Name Time Method Correlation between the change in BDNF levels and illness severity after treatment. pre and post treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do ECT and TMS differentially modulate BDNF signaling pathways in major depressive disorder?
What comparative effectiveness data exist for ECT versus TMS in altering BDNF levels in treatment-resistant depression?
Which serum biomarkers correlate with BDNF response to ECT or TMS in depressed patient subgroups?
What cognitive adverse events are associated with ECT and TMS in depression, and how are they mitigated?
Are there neurostimulation combinations or pharmacological agents that enhance BDNF upregulation in depression alongside ECT/TMS?
Trial Locations
- Locations (1)
Providence Care Mental Health Services
🇨🇦Kingston, Ontario, Canada
Providence Care Mental Health Services🇨🇦Kingston, Ontario, Canada